INTERogating Cancer for Etiology, Prevention and Therapy Navigation

(INTERCEPTioN Trial)

Recruiting at 2 trial locations

Overseen By Katie M. Gano, M.S.

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Mayo Clinic

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

2000 Participants Needed

Trial Summary

What is the purpose of this trial?

This study is being done to identify markers and causes of cancer by analyzing patient's DNA (i.e., genetic material), RNA, plasma, tissues, or other samples that could be informative for patients with cancer. Cancer genetic testing is a series of tests that finds specific changes in cancer cells and normal cells in the body. Researchers may request to access these data as they explore how to better prevent, screen, or treat cancer. This study is also being done to create a biobank (library) of samples and information to learn more about treating cancer. Discovery of genetic variants in patients with cancer could result in opportunities for cancer prevention, earlier diagnosis or better therapy for cancer.

Research Team

Jewel J. Samadder, M.D.

Principal Investigator

Mayo Clinic

Eligibility Criteria

Inclusion Criteria

I have a confirmed cancer diagnosis.

I can provide a sample of my blood, saliva, or hair.

I have undergone genetic testing for my condition.

Treatment Details

Participant Groups

Group I: Group B: Germline Testing Only Experimental Treatment 1 Intervention

Potential participants with a cancer diagnosis may be identified through the following sources: patients who will undergo or are currently undergoing clinical evaluation in practices such as, but not limited to, hematology-oncology, gastroenterology-hepatology, radiation-oncology and surgery. Participants will be enrolled in the study indefinitely unless a request to withdraw is made.

Group II: Group A: Germline and Somatic Testing Experimental Treatment 1 Intervention

Potential participants with a cancer diagnosis may be identified through the following sources: patients who will undergo or are currently undergoing clinical evaluation in practices such as, but not limited to, hematology-oncology, gastroenterology-hepatology, radiation-oncology and surgery. Participants will be enrolled in the study indefinitely unless a request to withdraw is made.

Who Is Running the Clinical Trial?

Mayo Clinic

Lead Sponsor

Trials

3,427

Recruited

3,221,000+